Navigation Links
Biopure's Stock Symbol Reverts to BPUR

CAMBRIDGE, Mass., Oct. 31 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that the trading symbol for its Class A common stock will revert from BPURD to BPUR at the open of the market on Wednesday, October 31, 2007. Outstanding warrants that trade on the OTCBB will revert to the following ticker symbols: BPREW reverting to BPURW; BPREZ reverting to BPURZ; and BPREL reverting to BPURL.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. Biopure has applied in the United Kingdom for regulatory approval of a proposed orthopedic surgical anemia indication. The company is developing Hemopure for several other indications and is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 bovine)], or HBOC-301, the only oxygen therapeutic approved by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 186,000 units of Oxyglobin, which have been used to treat an estimated 100,000 animals.

Statements in this release that are not strictly historical are forward- looking statements, including those statements implying that any planned clinical trial will be carried out or that study results will be as desired, statements related to the timing and response of the MHRA review and any statements that might imply that Hemopure may receive marketing approval in additional jurisdictions or for additional indications. Actual results and their timing may differ materially from those projected in these forward- looking statements due to risks and uncertainties. These risks include, without limitation, uncertainties regarding the company's financial position, including its limited cash resources and need to raise additional capital to pursue these initiatives, unexpected costs and expenses, delays and adverse determinations by regulatory authorities, unanticipated problems with the product's commercial use, whether or not product related, and with product distributors, sales agents or other third parties, delays in or unpredictable outcomes of clinical trials, and the other factors identified under the heading "Risk Factors" in the company's quarterly report on Form 10-Q filed on September 14, 2007, which can be accessed in the EDGAR database at the U.S. Securities and Exchange Commission's (SEC) website, The company undertakes no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof. A full discussion of the company's operations and financial condition can be found in the company's filings with the SEC.

The content of this release does not necessarily reflect the position or the policy of the U.S. Government or the Department of Defense, and no official endorsement should be inferred.

Contact: Tiana Gorham Herb Lanzet (Investors)

Biopure Corporation H.L. Lanzet Inc.

(617) 234-6826 (212) 888-4570

SOURCE Biopure Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Stockings Effective In Reducing The Effects Of Deep Vein Thrombosis
2. Risk of deep vein thrombosis less in people who were flight stockings when flying
3. Health and Human Services stockpiles 20 million bird flu Vaccines
4. Rich countries stock piling anti flu drugs with no stocks available for poor countries
5. Australian Government To Stockpile Anti-Bird Flu Drug Relenza
6. Bird Flu Threat Prompts Stockpiling Of Food And Medicine In America
7. Wake Up Call: U.N Takes Stock to Curb Fake Medicines Racket
8. Bird flu: the threat causes lowering in poultry stocks
9. OpenMED Nominated For Stockholm Challenge 2006 Award
10. Travel-Related Blood Clots Can Be Reduced By Using Flight Stockings
11. Time is ripe to take stock of depression
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... The Museum of Science & ... a new era of publicly accessible automated technology. Now, by popular demand, the ... guests an up-close look at the shuttle at MOSI’s main entrance. This experience ...
(Date:11/30/2015)... ... November 30, 2015 , ... The presidential race normally deals ... So why is it a national news story when Donald Trump makes disparaging remarks ... because appearances count more than anyone wants to admit when it comes to how ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... course in Dallas, TX, on January 29 and 30, 2016. The course welcomes ... functions of their practices, to learn how to better succeed in the modern ...
(Date:11/30/2015)... Georgia (PRWEB) , ... November 30, 2015 , ... ... of a key disease-causing component of bacteria could be effective in fighting methicillin-resistant ... at Georgia State University. , Their study showed that small molecule analogs that ...
(Date:11/30/2015)... ... November 30, 2015 , ... Dr. Seth D. Margulies specializes in orthodontics ... visit Dr. Margulies to experience the best available orthodontic experience in the area. ... Top Dentist"! , Orthodontics is the branch of dentistry that specializes in the diagnosis, ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Asia,s largest exhibition and conference dedicated to the Medical ...  - 22 nd April 2016. --> --> ... --> -->   --> ... aging population and the government back up, the Medical Device is one of ... States . With the aging population and the government back up, the ...
(Date:11/30/2015)... 30, 2015 Nevro Corp. (NYSE: NVRO ), ... solutions for the treatment of chronic pain, today announced that ... Patent and Trademark Office (USPTO) has denied instituting an ... (the ,102 patent).  --> ... Scientific Corporation filed two petitions challenging the validity of certain ...
(Date:11/30/2015)... , Nov. 30, 2015 ... of the "Orphan Drugs Market 2015-2019" ... ) has announced the addition of the ... offering. --> Research and Markets ( ... "Orphan Drugs Market 2015-2019" report to ...
Breaking Medicine Technology: